This phase II trial is trying to understand the safety and effectiveness of a targeted therapy drug (AFM13) in people with CD30-positive T-cell lymphoma.
This trial is treating patients with CD30-positive T-cell lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
This is a non-randomised trial with three cohorts, all receiving AFM13 via weekly intravenous infusions of 200mg. Cohort A will be PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%. Cohort B will be PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to <10%. cohort="" c="" will="" be="" tmf="" (transformed="" mycosis="" fungoides)="" patients="" with="" cd30="" expression="">10%.>
Recruiting Hospitals Read More